Abstract:Background and Objectives Pathogenic variants in the neuronal sodium channel α1 subunit gene ( SCN1A ) are the most frequent monogenic cause of epilepsy. Phenotypes comprise a wide clinical spectrum, including severe childhood epilepsy; Dravet syndrome, characterized by drug-resistant seizures, intellectual disability, and high mortality; and the milder genetic epilepsy with febrile seizures plus (GEFS+), characterized by normal cognition. Early recognition of a child9s risk for developing Dravet syndrome vs GEFS+ is key for implementing disease-modifying therapies when available before cognitive impairment emerges. Our objective was to develop and validate a prediction model using clinical and genetic biomarkers for early diagnosis of SCN1A -related epilepsies. Methods We performed a retrospective multicenter cohort study comprising data from patients with SCN1A -positive Dravet syndrome and patients with GEFS+ consecutively referred for genetic testing (March 2001–June 2020) including age at seizure onset and a newly developed SCN1A genetic score. A training cohort was used to develop multiple prediction models that were validated using 2 independent blinded cohorts. Primary outcome was the discriminative accuracy of the model predicting Dravet syndrome vs other GEFS+ phenotypes. Results A total of 1,018 participants were included. The frequency of Dravet syndrome was 616/743 (83%) in the training cohort, 147/203 (72%) in validation cohort 1, and 60/72 (83%) in validation cohort 2. A high SCN1A genetic score (133.4 [SD 78.5] vs 52.0 [SD 57.5]; p < 0.001) and young age at onset (6.0 [SD 3.0] vs 14.8 [SD 11.8] months; p < 0.001) were each associated with Dravet syndrome vs GEFS+. A combined SCN1A genetic score and seizure onset model separated Dravet syndrome from GEFS+ more effectively (area under the curve [AUC] 0.89 [95% CI 0.86–0.92]) and outperformed all other models (AUC 0.79–0.85; p < 0.001). Model performance was replicated in both validation cohorts 1 (AUC 0.94 [95% CI 0.91–0.97]) and 2 (AUC 0.92 [95% CI 0.82–1.00]). Discussion The prediction model allows objective estimation at disease onset whether a child will develop Dravet syndrome vs GEFS+, assisting clinicians with prognostic counseling and decisions on early institution of precision therapies (http://scn1a-prediction-model.broadinstitute.org/). Classification of Evidence This study provides Class II evidence that a combined SCN1A genetic score and seizure onset model distinguishes Dravet syndrome from other GEFS+ phenotypes.

Fine mapping and candidate gene analysis of Dravet syndrome modifier loci on mouse chromosomes 7 and 8

Fine Mapping and Candidate Gene Analysis of Dravet Syndrome Modifier Loci on Mouse Chromosomes 7 and 8

Clinical and Molecular Analysis of Epilepsy-Related Genes in Patients with Dravet Syndrome

Dravet syndrome with favourable cognitive and behavioral development due to a novel SCN1A frameshift mutation

Dravet syndrome and its mimics: Beyond SCN1A

Widespread genomic influences on phenotype in Dravet syndrome, a 'monogenic' condition

Neurodevelopmental defects in Dravet syndrome mice: targeting GABA-switch rescues behavioral dysfunctions but not seizures and mortality.

Do All Roads Lead to Rome? Genes Causing Dravet Syndrome and Dravet Syndrome-Like Phenotypes

Network‐based analysis predicts interacting genetic modifiers from a meta‐mapping study of spike–wave discharge in mice

Gabra2 is a genetic modifier of Scn8a encephalopathy in the mouse*

Study on the causative genes and analysis of genotypes and phenotypes of Dravet syndrome

Neurodevelopmental defects in Dravet syndrome mice: selective rescue of behavioral alterations but not seizures by targeting GABA-switch

SCN1A‐related phenotypes: Epilepsy and beyond

A more efficient conditional mouse model of Dravet syndrome: Implications for epigenetic selection and sex-dependent behaviors

Novel Mutations and Phenotypes of Epilepsy-Associated Genes in Epileptic Encephalopathies.

Gene Mutational Analysis in a Cohort of Chinese Children with Unexplained Epilepsy: Identification of a New KCND3 Phenotype and Novel Genes Causing Dravet Syndrome

Development and Validation of a Prediction Model for Early Diagnosis of SCN1A-Related Epilepsies

Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies

Dravet Syndrome-Associated Mutations in GABRA1, GABRB2 and GABRG2 Define the Genetic Landscape of Defects of GABAA Receptors

Functional and structural deficits of the dentate gyrus network coincide with emerging spontaneous seizures in an Scn1a mutant Dravet Syndrome model during development

A Novel Rat Model of Dravet Syndrome Recapitulates Clinical Hallmarks